RISK BASED INSPECTION [SCHEDULE M-POINT (14.3-14.5)]
![RISK BASED INSPECTION [SCHEDULE M-POINT (14.3-14.5)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-14.3-768x1086.jpg)
In a risk-based inspection (RBI), Schedule M points 14.3–14.5 are examined as high-impact controls because they govern how a firm handles nonconforming APIs/intermediates, recovered materials/solvents, and returned goods—all common sources of hidden quality defects, impurity drift, contamination, and data integrity…





![RISK BASED INSPECTION [SCHEDULE M-POINT (14.2)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-14.2-768x1087.jpg)
![RISK BASED INSPECTION [SCHEDULE M-POINT (14.1)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-14.1-768x1087.jpg)
![RISK BASED INSPECTION [SCHEDULE M & WHO TRS 986-POINT (13.6-13.10)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-WHO-TRS-986-13.6-13.10-768x1086.jpg)
![RISK BASED INSPECTION [SCHEDULE M & WHO TRS 986-POINT (13.2-13.5)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-WHO-TRS-986-13.2-13.5-768x1086.jpg)
![RISK BASED INSPECTION [SCHEDULE M-POINT (13.1)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-13.1-768x1086.jpg)
![RISK BASED INSPECTION [WHO TRS 986-POINT (12.6-12.10)]](https://pharmadevils.com/wp-content/uploads/2024/10/WHO-TRS-986-12.6-12.10-768x1086.jpg)
![RISK BASED INSPECTION [WHO TRS 986-POINT (12.4-12.5)]](https://pharmadevils.com/wp-content/uploads/2024/10/WHO-TRS-986-12.4-12.5-768x1086.jpg)
![RISK BASED INSPECTION [SCHEDULE M & WHO TRS 986-POINT (12.1-12.3)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-WHO-TRS-986-12.1-12.3-768x1087.jpg)
![RISK BASED INSPECTION [WHO TRS 986-POINT (11.16-11.20)]](https://pharmadevils.com/wp-content/uploads/2024/10/WHO-TRS-986-11.16-11.20-768x1087.jpg)